Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

IBD in 2017

Development of therapy for and prediction of IBD — getting personal

Nature Reviews Gastroenterology & Hepatology volume 15, pages 72–74 (2018)Cite this article

Subjects

The central studies published in 2017 address novel IBD therapeutic strategies and prediction of the future disease course or response to a distinct therapy. Together, these studies contribute to the understanding of the regulation of mucosal homeostasis and at the same time serve to develop novel personalized treatment algorithms in patients in whom a severe disease course can be predicted.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The complex interplay between environment and host in IBD.

References

  1. Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118–1125 (2010).

    Article  CAS  Google Scholar 

  2. Paramsothy, S. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389, 1218–1228 (2017).

    Article  Google Scholar 

  3. Siegmund, B. Is intensity the solution for FMT in ulcerative colitis? Lancet 389, 1170–1172 (2017).

    Article  Google Scholar 

  4. Feagan, B. G. et al. Ustekinumab as induction and maintenance therapy for Crohn's Disease. N. Engl. J. Med. 375, 1946–1960 (2016).

    Article  CAS  Google Scholar 

  5. Feagan, B. G. et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389, 1699–1709 (2017).

    Article  CAS  Google Scholar 

  6. Sands, B. E. et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study. Gastroenterology 153, 77–86.e6 (2017).

    Article  CAS  Google Scholar 

  7. West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat. Med. 23, 579–589 (2017).

    Article  CAS  Google Scholar 

  8. Atreya, R. et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat. Med. 20, 313–318 (2014).

    Article  CAS  Google Scholar 

  9. Lee, J. C. et al. Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. Nat. Genet. 49, 262–268 (2017).

    Article  CAS  Google Scholar 

  10. Plomin, R., Haworth, C. M. & Davis, O. S. Common disorders are quantitative traits. Nat. Rev. Genet. 10, 872–878 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine 1, University of Erlangen-Nuremberg, Ulmenweg 18, Erlangen, 91054, Germany

    Raja Atreya

  2. Medizinische Klinik für Gastroenterologie, Infektiologie, Rheumatologie, Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12200, Germany

    Britta Siegmund

Authors
  1. Raja Atreya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Britta Siegmund
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Britta Siegmund.

Ethics declarations

Competing interests

R.A. served as consultant for Abbvie, Janssen and Pfizer, and received speaker's fees from Abbvie, Falk, Janssen, MSD and Takeda. B.S. received a research grant from Pfizer, served as consultant for Falk, Janssen, MSD, Abbvie, Takeda and Hospira, and received lecture fees from Abbvie, Falk, Ferring, MSD, Merck and Takeda; all money went to the Charité–Universitätsmedizin Berlin, Germany.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Atreya, R., Siegmund, B. Development of therapy for and prediction of IBD — getting personal. Nat Rev Gastroenterol Hepatol 15, 72–74 (2018). https://doi.org/10.1038/nrgastro.2017.166

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2017.166

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing